| |
Learn how Transmission Electron Microscopy (TEM) enables precise quantification of virus-like particles (VLPs) in unprocessed bulk material. Discover the importance of TEM in viral safety testing and cell line characterization. Check out our scientific poster! .png)
|
|
Today’s Big NewsOct 23, 2024 |
|
Wednesday, October 29, 2024 | 11am ET / 8am PT Real-world data is essential to gaining insights into a patient’s diagnostic journey. However, many pharma companies may not be using lab data to its full potential. Join us to discuss how today’s robust lab data sources can help improve patient access and time to treatment, leading to better patient outcomes. Register now. 
|
|
| By Kevin Dunleavy Novo Nordisk has asked the FDA to prevent compounders from manufacturing copycat versions of its juggernaut diabetes and obesity treatments Ozempic and Wegovy, claiming the drugs are too complex to safely replicate. |
|
|
|
By Nick Paul Taylor Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate disappointed in phase 2, disclosed the setback as part of a wider pullback from prospects that fell short of the bar for further development. |
By Darren Incorvaia Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma. |
By Fraiser Kansteiner While Novo Holdings and Catalent continue to voice confidence that their planned $16.5 billion merger will go through before the year is out, the deal has received near-constant criticism over the past several weeks. Now, a new complaint has surfaced—not from lawmakers or consumer groups but a major pharma CEO. |
By Ben Adams As we head towards Lung Cancer Awareness Month in November disease healthcare organization LUNGevity Foundation is launching a new awareness campaign with backing from major lung cancer drug players. |
By Conor Hale Boston Scientific is keeping the ball rolling in pulsed field ablation, with sales ahead of projections and global expansions on the horizon. But the company also paused a study exploring Farapulse as a first-line afib therapy. |
By Fraiser Kansteiner Amgen is preparing to launch its Eylea biosimilar, Pavblu, after another victory over Regeneron in court. That said, Regeneron is appealing the decision and stressed that it continues to believe Amgen's copycat infringes multiple Eylea patents. |
By Andrea Park As it prepares to submit its molgramostim inhalation solution for FDA approval to treat autoimmune pulmonary alveolar proteinosis, Savara is laying some groundwork in raising awareness of the rare disease. |
By Nick Paul Taylor Alto Neuroscience hit a bum note in an early test of its precision neuropsychiatry model. A phase 2b trial of Alto’s lead drug candidate in depression missed its primary and key secondary endpoints, prompting investors to wipe 60% off the biotech’s share price. |
By Nick Paul Taylor There’s change at the top of Ogilvy Health. Kim Johnson is leaving to pursue new opportunities after three years as CEO, driving Ogilvy Health to hire Mario Muredda from Avalere Health to fill the vacancy. |
By James Waldron Alpha-9 Oncology has raised a $175M series C to fund its clinical-stage radiopharma drugs, although the exact details of the biotech’s pipeline remain hazy for now. |
By Zoey Becker Lilly's Alzheimer's treatment fell to the same fate as Biogen and Eisai's rival Leqembi in the U.K., with the region's cost watchdog declining to support reimbursement through its National Health Service. |
By Nick Paul Taylor ICR has united the fruits of its acquisition-driven push into healthcare under a single brand. Around one year after closing the second of two key acquisitions, the communications firm has brought its assets together to create ICR Healthcare. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” we catch up with three past Fierce 15 honorees to gain their insights, experiences and visions for the evolving biotech landscape. |
|
|---|
|
|
|
Thursday, November 14, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
